Key stats
Market capitalization
15MUSD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−15.22USD
About Cellectar Biosciences, Inc
ISIN
US15117F8077
Sector
Health Technology
Industry
Pharmaceuticals: Major
Website
cellectar.com
CEO
James V. Caruso
Headquarters
Florham Park
Employees
15
Founded
1996
Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124 which could detect tumors and metastases in a broad range of cancers and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June 1996 and is headquartered in Florham Park, NJ.
$CLRB can rise in the next daysContextual immersion trading strategy idea.
Cellectar Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer.
The demand for shares of the company looks higher than the supply.
This and othe
Long Upside but needs more volume. They have an upside price target of 5.40. There a few resistance points but I will probably set my long term target at the top green marker on the chart. A downfall from time to time is the volume on this stock.
Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, focuses o
See all ideas
Income Statement
Balance Sheet
Cash Flow
Earnings
Next:—
0
Revenue
0